In the context of fierce competition in the domestic pharmaceutical market, "license out" has become the main model of domestic pharmaceutical companies going to sea in recent years, this kind of advantage of borrowing "ship" to go to sea is outstanding, on the one hand, it can help pharmaceutical companies to achieve complementary advantages at the research and development end, reduce the risk of new drug research and development, on the other hand, pharmaceutical companies can also use the sales channels of multinational pharmaceutical companies at the sales end to make domestic innovative drugs appear on the international stage faster, and obtain return funds to feed the company's follow-up independent research and development projects
.
According to industry statistics, in the first half of 2022, a total of 28 domestic pharmaceutical companies borrowed "boats" to go to sea, including Junshi Biological, Cinda/Reindeer Medical, Tianyan Pharmaceutical, Colombota, Hebo Pharmaceutical, Duoxi Biological, Bai o'othitu, etc.
In the first half of the year, the total amount of license out transactions reached 5.
67 billion US dollars, and heavy transactions appeared
frequently.
For example, on July 26, Kelun Pharmaceutical announced that its holding subsidiary, Coloum Pateo, has granted a paid exclusive license to Merck for research, development, manufacturing and commercialization
of a clinical early biological macromolecule oncology project B with independent intellectual property rights.
Under the agreement, Colombott will receive a non-refundable down payment of $35 million, with milestone payments totaling no more than $901 million, and a percentage of net sales agreed upon by the parties
.
On April 7, AstraZeneca announced a global licensing agreement
with AstraZeneca for the development and commercialization of clDN18.
2xCD3 bispecific antibody (HBM7022).
Under the agreement, AstraZeneca will receive an exclusive global interest in HBM7022, and HeboM will receive an advance payment of $25 million and a milestone payment of up to $325 million, as well as a royalty based on future HBM7022 sales
.
In March, Tianyan Pharmaceutical and Sanofi reached a technology licensing agreement with a potential value of up to $
2.
5 billion.
The partnership includes a $17.
5 million down payment, potential milestone payments of up to $2.
5 billion ($625 million per project), and tiered royalties
.
The industry said that the completion of these large-scale foreign authorization transactions shows that the innovative strength behind domestic pharmaceutical companies is being recognized by
foreign capital.
At present, the model of innovative pharmaceutical companies going to sea includes independent going to sea, borrowing "boats" to go to sea, joining hands to go to sea, etc.
Since the beginning of this year, including Xindili monoclonal antibody of Cinda Biologics, Triplixumab of Junshi Biology, BeiGene's tirelizumab monopharmaceutumab and other domestic innovative drugs represented by PD-1 tumor drugs have been frequently frustrated, and pharmaceutical companies have made it easier to control risks by borrowing "ships" to go to sea, or to help local innovative pharmaceutical companies enter the international market
faster.
It is worth mentioning that license out is not smooth all the way, and some pharmaceutical companies have failed to license out before
.
In this regard, the industry pointed out that whether a pipeline product can successfully license out, in fact, it can be judged when the project is formed, so it is necessary to select
a good target and indication.
The above-mentioned person said that relatively speaking, many domestic pharmaceutical companies will appear "unsatisfied" when they go out, find suitable partners through License-out, and rely on their advantages in local clinical research and development and commercialization, and can be more quickly integrated into the local market
.
However, the market demand and policy tendencies of different target markets are different, and it is recommended that pharmaceutical companies find suitable business partners in stages and regions, and the formulation of business strategies and cooperation strategies should also be adapted to local conditions
.
At the same time, it is also necessary to see that no matter which way of going to sea has advantages and disadvantages, enterprises should choose according to
their own situation.
